Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab
GO40554
Phase 2 small_molecule active
Quick answer
Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab for Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active